Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Internal Medicine, MedStar Washington Hospital Center, Washington, DC, USA.
Leukemia. 2018 Jan;32(1):131-138. doi: 10.1038/leu.2017.204. Epub 2017 Jun 27.
Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.
（11；14）易位在浆细胞间期荧光原位杂交中被认为是多发性骨髓瘤的标准风险预后标志物，这一结论基于当前疗法引入之前的研究。我们鉴定了 365 例 t（11；14）患者和 730 例匹配对照：132 例非（11；14）易位患者和 598 例无染色体易位患者。三组患者的中位无进展生存期分别为 23.0（95%置信区间（CI），20.8-27.6）、19.0（95%CI，15.8-22.7）和 28.3（95%CI，25.7-30.6）个月（P<0.01）。t（11；14）、非（11；14）易位和无易位组的中位总生存期（OS）分别为 74.4（95%CI，64.8-89.3）、49.8（95%CI，40.0-60.6）和 103.6（95%CI，85.2-112.3）个月（P<0.01）。排除 17p 异常患者后，三组患者的中位 OS 分别为 81.7（95%CI，67.0-90.7）、58.2（95%CI，47.0-76.4）和 108.3（95%CI，92.4-140.1）个月（P<0.01）。在年龄<65 岁、国际分期系统（ISS）I/II 期或接受新型药物诱导的患者中，这种关系仍然成立。在 t（11；14）患者中，年龄较大（危险比（HR）：1.98）、17p 异常（HR：2.2）和 ISS III 期（HR：1.59）与 OS 降低相关。这些结果表明，t（11；14）MM 的结局劣于其他标准风险患者。
